Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Case study update: alpelisib for the treatment of PI3K-driven Langerhans cell histiocytosis

Roei Mazor • 10 Jun 2022
EHA 2022
Histiocytosis Langerhans Cell Histiocytosis Non-Malignant Rare Diseases Alpelisib

Roei Mazor, MD, PhD, Assuta Medical Center, Tel Aviv, Israel, discusses a case study in which a patient with PI3K-driven Langerhans cell histiocytosis was treated with alpelisib. Dr Mazor first highlights driver mutations commonly found in this rare disease and then discusses the impressive results observed with the use of alpelisib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Roei Mazor

2:11
Types of histiocytosis and their treatment strategies
Roei Mazor • 10 Jun 2022
2:13
An insight into Langerhans cell histiocytosis and advances in treatment approaches
Roei Mazor • 10 Jun 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals